ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease

R Perondi1, A Saino, R A Tio

  • 1Cattedra di Medicina Interna (Ospedale S. Gerardo, Monza), Milan, Italy.

Circulation
|June 1, 1992
PubMed

Insights

Angiotensin converting enzyme (ACE) inhibition reduces sympathetic coronary vasoconstriction in patients with coronary artery disease. This effect is likely due to blocking angiotensin II's influence on coronary blood flow regulation.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Sympathetic stimulation typically causes vasoconstriction in peripheral arteries.
  • The effect of angiotensin converting enzyme (ACE) inhibition on sympathetic coronary vasoconstriction is not well understood.

Purpose of the Study:

  • To investigate whether ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease.

Main Methods:

  • Nine patients with coronary atherosclerosis underwent cold pressor tests and diving stimuli.
  • Measurements included arterial pressure, heart rate, coronary sinus blood flow (CBF), and coronary vascular resistance (CVR).
  • Measurements were taken before and after oral administration of captopril (an ACE inhibitor).

Main Results:

  • Without captopril, sympathetic stimuli increased coronary vascular resistance (CVR) and reduced coronary blood flow (CBF).
  • Captopril did not significantly alter blood pressure or heart rate responses to stimuli.
  • Captopril markedly attenuated the increase in CVR during sympathetic stimulation.

Conclusions:

  • ACE inhibition effectively reduces sympathetic coronary vasoconstriction in patients with coronary artery disease.
  • This attenuation is likely mediated by the removal of angiotensin II's facilitating effect on sympathetic coronary vasomotor tone.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...